Results 191 to 200 of about 391,733 (291)

PTPN18 functions as a tumor suppressor in breast cancer by negatively regulating cyclin E. [PDF]

Int J Oncol
Zhang N, Wang T, Bai B, Zhang X, Xu W, Chen W, Yu Y, Wang B.   +7 more
europepmc   +1 more source

Wogonin as a potential therapeutic agent for psoriasis: Core target identification and validation. [PDF]

Exp Ther Med
Lu Y, Zhou X, Guo Y, Zhang F, Wang J, Ge J, Xiao Y, Yang D.   +7 more
europepmc   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

The TWEAK-HOIP-HuR Axis: A Novel Mechanism of AMPK Inactivation and Metabolic Reprogramming in Lupus Nephritis Mesangial Cells Hyperproliferation. [PDF]

Mediators Inflamm
Ding Z, Liu E, Li X, Zhang Y, Li L, Weng C, Liu Z, Liu Z.   +7 more
europepmc   +1 more source

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source

Frontiers in Cell-Cycle-Targeting Therapies: Addressing the Heterogeneity of the Cancer Cell Cycle. [PDF]

Cancers (Basel)
Ganesan IP, Kiyokawa H.
europepmc   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Precision targeting of <i>CCNE1</i>-amplified tumors-lessons from BLU-222 and beyond. [PDF]

Transl Cancer Res
Rantanen F, Ungureanu D.
europepmc   +1 more source

PVT1 lincRNA signals an androgen‐dependent transcriptional activation program of oncogenes in prostate cancer cells

International Journal of Cancer, EarlyView.
What's New? Unraveling the networks that regulate androgen receptor (AR) function is critical to better understanding prostate cancer development and progression. Of particular interest in this regard is the long non‐coding RNA PVT1, which regulates gene expression in cancer and is upregulated in prostate tumors.
Maria Gabriela Berzoti‐Coelho, Fabio Nunes de Mello, Ana Carolina Tahira, Gabriel Nakanishi Fortes, Agatha Fischer‐Carvalho, Pedro Jardim Poli, Murilo Sena Amaral, Sergio Verjovski‐Almeida   +7 more
wiley   +1 more source

SKA2 promotes gastric cancer progression by regulating glutathione metabolism. [PDF]

iScience
Zhang P, Zhong J, Zhou T, Jiang D, Wang Z, Ye M, Fang L, Xiong H, Chen H.   +8 more
europepmc   +1 more source